| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant human protein (amino acids R29-K431) was used as the immunogen for the Integrin beta 4 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Integrin beta 4 Antibody / ITGB4 / CD104 is an antibody targeting ITGB4, raised in Mouse for protein detection and localization studies where these specifications are required.
Key elements and design rationale
- Target: ITGB4.
- Antibody identity: Monoclonal (mouse origin); Clone 7G10D2; Mouse IgG2b.
- Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
- Format: Antigen affinity purified.
- Species reactivity: Human.
- Listed applications: WB, IF, FACS (refer to on-page specifications for application-specific guidance).
Biological background
ITGB4 (Integrin, beta-4), also known as CD104 (Cluster of Differentiation 104), is a human gene. The gene encodes the integrin beta 4 subunits, a receptor for the laminins. This subunit tends to associate with alpha 6 subunits and is likely to play a pivotal role in the biology of invasive carcinoma. The ITGB4 gene is mapped on 17q25.1. Using expression profiling, Yang et al. found that ITGB4 was upregulated 6-fold by ZKSCAN3 in transfected human colon cancer cells compared with parental cells. They confirmed that ZKSCAN3 bound the promoter of ITGB4 in vitro and in vivo. ITGB4 knockdown by short hairpin RNA countered ZKSCAN3-augmented anchorage-independent colony formation in the colon cancer cell lines. The integrin beta-4 subunit is characterized by an unusually long cytoplasmic domain that harbors 4 fibronectin type III (FNIII) repeats, residing in 2 pairs separated by a connecting segment. Vidal et al. found compound heterozygosity for mutations in the ITGB4 gene in an infant with junctional epidermolysis bullosa associated with pyloric atresia.
Research relevance and current trends
- Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
- Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
- Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.
Common research applications
- Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
- Immunofluorescence: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
- Flow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.
Notes for experimental interpretation
- Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
- Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
- Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
- Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
